Australia markets close in 1 hour 55 minutes

Bellicum Pharmaceuticals, Inc. (BLCM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4000+0.1200 (+9.38%)
At close: 03:58PM EST
1.4300 +0.03 (+2.14%)
After hours: 06:51PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.2800
Open1.3000
Bid1.3900 x 800
Ask1.4200 x 900
Day's range1.2600 - 1.4300
52-week range0.6000 - 2.2000
Volume47,410
Avg. volume41,471
Market cap12.059M
Beta (5Y monthly)1.38
PE ratio (TTM)11.67
EPS (TTM)0.1200
Earnings date22 Mar 2023 - 27 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.00
  • GlobeNewswire

    CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 45,000, as previously stated. The corrected release follows: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 20,000 stock options. Th

  • GlobeNewswire

    Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of January 31, 2023. The stock options were granted as inducements material to the employees entering into employment with

  • GlobeNewswire

    Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium

    HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The meeting is being held February 16-18, 2023 in San Francisco